# US 2023/0391835 A1 · Compositions relating to a mutant clostridium difficile toxin and methods thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0391835 A1
- Document ID: US20230391835A1
- Status: Published application
- Kind: A1
- Application number: 18/066,591
- Filed: 2022-12-15
- Published: 2023-12-07
- Earliest claimed: 2011-04-22
- Assignees: Wyeth
- Applicants: Wyeth LLC
- Inventors: Kathrin Ute Jansen; Annaliesa Sybil Anderson; Robert G.K. Donald; Maninder K. Sidhu; Narender Kumar Kalyan; Justin Keith Moran; Mark Edward Ruppen; Michael James Flint
- Web page: https://patentgrep.com/patent/US20230391835A1

## CPC

- C07K 14/33: from Clostridium (G)
- A61K 39/08: Clostridium, e.g. Clostridium tetani
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 31/04: Antibacterial agents
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- C07K 16/1282: Clostridium (G)
- C12N 9/1051: {Hexosyltransferases (2.4.1)}
- C12N 9/99: Enzyme inactivation by chemical treatment
- C12N 15/74: Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.

## Claims

### Claim at position 1

1-36. (canceled)

### Claim 37

An immunogenic composition comprising a mutant Clostridium difficile toxin A, which comprises a glucosyltransferase domain having at least two mutations and a cysteine protease domain having at least one mutation, according to the numbering of SEQ ID NO:1, and wherein the methionine at position 1 of SEQ ID NO:1 is absent.

### Claim 38 (depends on 37)

The immunogenic composition of claim 37, wherein the glucosyltransferase domain comprises at least two mutations present at amino acid positions 101, 269, 272, 285, 287, 460, 462, 541, or 542.

### Claim 39 (depends on 37)

The immunogenic composition of claim 37, wherein the glucosyltransferase domain comprises at least two mutations selected from W101A, D269A, R272A, D285A, D287A, E460A, R462A, S541A, and L542G.

### Claim 40 (depends on 37)

The immunogenic composition of claim 37, wherein the glucosyltransferase domain comprises mutations D285A and D287A.

### Claim 41 (depends on 37)

The immunogenic composition of claim 37, wherein the cysteine protease domain comprises at least one mutation present at amino acid positions 543, 589, 655, or 700.

### Claim 42 (depends on 37)

The immunogenic composition of claim 37, wherein the cysteine protease domain comprises at least one mutation selected from S543A, D589A, D589N, H655A, and C700A.

### Claim 43 (depends on 37)

The immunogenic composition of claim 37, wherein the cysteine protease domain comprises mutation C700A.

### Claim 44

An immunogenic composition comprising a mutant Clostridium difficile toxin B, which comprises a glucosyltransferase domain having at least two mutations and a cysteine protease domain having at least one mutation, according to the numbering of SEQ ID NO:2, and wherein the methionine at position 1 of SEQ ID NO:2 is absent.

### Claim 45 (depends on 44)

The immunogenic composition of claim 44, wherein the glucosyltransferase domain comprises at least two mutations present at amino acid positions 102, 270, 273, 286, 288, 384, 461, 463, 520, or 543.

### Claim 46 (depends on 44)

The immunogenic composition of claim 44, wherein the glucosyltransferase domain comprises at least two mutations selected from W102A, D270A, D270N, R273A, D286A, D288A, N384A, D461A, D461R, K463A, K463E, W520A, and L543A.

### Claim 47 (depends on 44)

The immunogenic composition of claim 44, wherein the glucosyltransferase domain comprises mutations D286A and D288A.

### Claim 48 (depends on 44)

The immunogenic composition of claim 44, wherein the cysteine protease domain comprises at least one mutation present at amino acid positions 544, 587, 653, or 698.

### Claim 49 (depends on 44)

The immunogenic composition of claim 44, wherein the cysteine protease domain comprises at least one mutation selected from G544A, D587A, D587N, H653A and C698A.

### Claim 50 (depends on 44)

The immunogenic composition of claim 44, wherein the cysteine protease domain comprises mutation C698A.

### Claim 51

An immunogenic composition comprising a mutant Clostridium difficile toxin A, which comprises a mutation at amino acid positions 285, 287, and 700, according to the numbering of SEQ ID NO:1, and wherein the methionine at position 1 of SEQ ID NO:1 is absent, and a mutant Clostridium difficile toxin B, which comprises a mutation at amino acid positions 286, 288, and 698, as compared to SEQ ID NO:2, and wherein the methionine at position 1 of SEQ ID NO:2 is absent.

### Claim 52 (depends on 51)

The immunogenic composition of claim 51, wherein the mutant C. difficile toxin A comprises the mutations D285A, D287A, and a C700A, and the mutant C. difficile toxin B comprises mutations D286A, D288A, and C698A.

### Claim 53 (depends on 51)

The immunogenic composition of claim 51, wherein each mutant C. difficile toxin comprises at least one of:
a) a crosslink between a side chain of an aspartic acid residue of the polypeptide and a side chain of a lysine residue of the polypeptide;
b) a crosslink between a side chain of a glutamic acid residue of the polypeptide and a side chain of a lysine residue of the polypeptide;
c) a beta-alanine moiety linked to a side chain of at least one lysine residue of the polypeptide; and
d) a glycine moiety linked to a side chain of at least one aspartic acid residue of the polypeptide or to a side chain of at least one glutamic acid residue of the polypeptide.

### Claim 54 (depends on 51)

The immunogenic composition of claim 51, wherein at least one amino acid is chemically crosslinked.

### Claim 55 (depends on 54)

The immunogenic composition of claim 54, wherein the at least one amino acid is crosslinked by 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC).

### Claim 56 (depends on 54)

The immunogenic composition of claim 54, wherein the at least one amino acid is crosslinked by N-hydroxysuccinimide (NHS).
